中国肺癌杂志2025，Vol.28Issue(6)：472-476,5.DOI:10.3779/j.issn.1009-3419.2025.102.25
肺腺癌化疗联合PD-1单抗免疫治疗继发重度贫血病例报道及文献复习
Case Report and Literature Review of Severe Anemia Secondary to Chemotherapy Combined with PD-1 Monoclonal Antibody Immunotherapy for Lung Adenocarcinoma
摘要
Abstract
Programmed cell death 1(PD-1)inhibitor therapy for lung adenocarcinoma may induce rare but severe hematologic adverse events,including severe anemia.Although glucocorticoids are recommended for managing immune-related adverse events,therapeutic experience with PD-1 inhibitor-induced severe anemia remains limited,and its efficacy and safety have not been fully validated.This article reports a case of advanced lung adenocarcinoma in which severe anemia devel-oped following combination therapy with chemotherapy and PD-1 inhibitor.After comprehensive evaluation,the patient was diagnosed with anemia of inflammation(AI)and achieved significant hemoglobin recovery following high-dose glucocorticoid treatment.These findings may provide new insights into the recognition and management of this rare hematologic toxicity in clinical practice.关键词
肺肿瘤/免疫检查点抑制剂/程序性细胞死亡受体1/免疫相关不良事件/贫血Key words
Lung neoplasms/Immune checkpoint inhibitors/Programmed cell death 1/Immune-related adverse events/Anemia引用本文复制引用
胡耀文,赵静,高晓星,徐燕,王孟昭..肺腺癌化疗联合PD-1单抗免疫治疗继发重度贫血病例报道及文献复习[J].中国肺癌杂志,2025,28(6):472-476,5.基金项目
This paper was supported by the grant from National High Level Hospital Clinical Research Funding(No.2022-PUMCH-C-054)(to Yan XU). 本文受北京协和医院中央高水平医院临床科研专项(No.2022-PUMCH-C-054)资助 （No.2022-PUMCH-C-054）
